About Affimed NV
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes FM13, AFM11, AFM21, AFM22, AFM24, TandAb and Trispecific Abs. It has started recruitment for Phase IIa clinical trial of AFM13 in patients with Hodgkin Lymphoma. It has initiated a Phase I clinical trial of AFM11 in patients with non-Hodgkin Lymphoma. AFM21 is in preclinical development. AFM22, which is an Epidermal Growth Factor Receptor variant III (EGFRvIII)/CD16A NK-cell TandAb is in preclinical development. AFM24 is an additional CD16A NK-cell TandAb targeting a validated solid tumor target, EGFR-wild type. It is developing Trispecific Abs for treating multiple myeloma, and CD33/CD3-specific T-cell TandAb to treat acute myeloid leukemia.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: AFMD
- Previous Close: $2.00
- 50 Day Moving Average: $2.04
- 200 Day Moving Average: $2.31
- 52-Week Range: $1.65 - $5.00
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -1.75
- P/E Growth: 0.00
- Market Cap: $66.42M
- Outstanding Shares: 33,209,000
- Beta: 3.63
- Net Margins: -501.31%
- Return on Equity: -57.35%
- Return on Assets: -48.29%
Companies Related to Affimed NV:
- Debt-to-Equity Ratio: 0.04%
- Current Ratio: 6.27%
- Quick Ratio: 6.24%
Earnings History for Affimed NV (NASDAQ:AFMD)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|3/28/2017|| || || || || || || || |
|11/2/2016||Q316||($0.26)||($0.31)||$2.65 million||$0.94 million||View||N/A|
|8/10/2016||Q216||($0.22)||($0.24)||$2.10 million||$2.07 million||View||Listen|
|5/18/2016||Q116||($0.17)||($0.25)||$1.88 million||$1.90 million||View||Listen|
|3/30/2016||Q415||($0.18)||($0.22)||$1.71 million||$1.66 million||View||Listen|
|11/10/2015||Q315||($0.25)||($0.24)||$1.87 million||$1.20 million||View||Listen|
|8/4/2015||Q215||($0.14)||($0.21)||$2.56 million||$2.21 million||View||N/A|
Earnings Estimates for Affimed NV (NASDAQ:AFMD)
Current Year EPS Consensus Estimate: $-1.14 EPS
Next Year EPS Consensus Estimate: $-1.14 EPS
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Affimed NV (NASDAQ:AFMD)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Affimed NV (NASDAQ:AFMD)
No insider trades for this company have been tracked by MarketBeat.com
Latest Headlines for Affimed NV (NASDAQ:AFMD)
What is Affimed NV's stock symbol?
Affimed NV trades on the NASDAQ under the ticker symbol "AFMD."
Where is Affimed NV's stock going? Where will Affimed NV's stock price be in 2017?
4 brokers have issued 12 month target prices for Affimed NV's shares. Their predictions range from $2.00 to $7.00. On average, they anticipate Affimed NV's stock price to reach $4.33 in the next twelve months.
When will Affimed NV announce their earnings?
Affimed NV is scheduled to release their next quarterly earnings announcement on Tuesday, March, 28th 2017.
Who owns Affimed NV stock?
Affimed NV's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Orbimed Advisors LLC (10.16%), Bain Capital Public Equity Management LLC (6.32%) and Perceptive Advisors LLC (2.21%).
Who bought Affimed NV stock? Who is buying Affimed NV stock?
Affimed NV's stock was acquired by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC.
How do I buy Affimed NV stock?
Shares of Affimed NV can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Affimed NV stock cost?
One share of Affimed NV stock can currently be purchased for approximately $2.00.
Affimed NV (NASDAQ:AFMD) Chart for Friday, February, 24, 2017
Institutional Ownership ChartEarnings History ChartDividend History Chart